Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences, Inc. (NASDAQ:XBIO) saw a large increase in short interest in August. As of August 14th, there was short interest totaling 45,169 shares, an increase of 299.3% from the July 30th total of 11,313 shares. Based on an average daily volume of 111,557 shares, the short-interest ratio is presently 0.4 days. Currently, 2.1% of the company’s stock are sold short.

Xenetic Biosciences Price Performance

XBIO opened at $3.98 on Friday. Xenetic Biosciences has a fifty-two week low of $1.90 and a fifty-two week high of $13.93. The firm has a market capitalization of $9.11 million, a PE ratio of -3.43 and a beta of 2.10. The company’s 50-day moving average is $3.00 and its 200 day moving average is $2.93.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter. The company had revenue of $0.66 million for the quarter. Xenetic Biosciences had a negative net margin of 75.90% and a negative return on equity of 40.62%.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. DRW Securities LLC purchased a new stake in Xenetic Biosciences, Inc. (NASDAQ:XBIO) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned about 0.60% of Xenetic Biosciences at the end of the most recent quarter. Institutional investors and hedge funds own 15.12% of the company’s stock.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.